Stem Cells: Ability for Liver Regeneration | Dr. David Greene Arizona

Millions of people throughout the world suffer from end-stage liver disease, for which liver transplantation is the only treatment option (OLT). Alternatives to OLT, such as cell treatments, have been considered in light of the donor organ shortage. The use of hepatocyte transplantation to treat metabolic liver illnesses and end-stage liver diseases has been attempted.

The scarcity of human hepatocytes, as well as their problematic growth and cryopreservation, make evaluating its efficacy difficult. Due to researchers like Dr. David Greene Arizona, the notion of "regenerative medicine," based on the therapeutic potential of stem cells, has emerged as a result of recent advancements in cell biology (SCs). Different types of SCs might hypothetically be used to replace liver cells. Embryonic and fetal SCs, induced pluripotent cells, neonatal SCs, endogenous liver SCs, and extrahepatic adult SCs are all examples of these cells. The purpose of this study is to critically evaluate the various options available.

Several stem cell-based therapies for liver diseases have been proposed, including extracorporeal bioartificial liver devices, cell transplantation, and tissue-engineered structures, due to the ongoing donor shortage. Despite their distinctions, these treatments all require a sufficient supply of cells and the stability of liver-specific processes.

Although certain extracorporeal cell-based support devices are now in clinical trials, strategies for enhancing stem cell-derived hepatocyte function can increase the efficacy of modified cell therapies in the therapy of liver disease.

Current cell-based techniques will use a number of cell sources, including primary cells and stem cells, to interact with the milieu and provide crucial liver-specific activities. To implement such measures, learning from classic liver biology as well as transplant medicine's expertise supporting liver failure patients must be drawn.

Induced pluripotent stem cells (iPSs), which were recently described, may be able to avoid the ethical difficulties and danger of rejection associated with embryonic and fetal liver SCs. Indeed, iPSs are embryonic-like SCs produced from somatic cells via reprogramming factors that are forced to be expressed. iPSs may theoretically be created from the same patient and used for tissue regeneration or gene therapy.

Scientists and Researchers like Dr. David Greene Orthopedic Surgeon are focusing on hepatocytes derived from bone marrow or embryonic stem cells and their interactions with their microenvironment, as well as developing microfabrication tools to improve cellular therapies for liver disease, particularly cell-cell and cell-extracellular matrices (ECMs) interactions on stem cell differentiation and mechanism.

The coculture system and 3D organoid culture in bioreactors have been utilized to increase fundamental understanding of liver physiology and pathophysiology, as well as to maximize hepatocyte function and simplify the design of effective cellular treatments for liver illness. 

Then, using biofabrication, researchers built an implanted bioartificial liver assist system using stem cell generated hepatocytes as seed cells and investigated the impact of biochemical and mechanical characteristics on hepatic modality, structure, and function.

Scientists such as Dr. David Greene Arizona show their interest in employing hepatic oval cell arrays as high-throughput platforms for studying fundamental elements of stem cell biology (Cell-Based BioMEMS) with a variety of techniques (Cell-Based BioMEMS), suggesting a new hypothesis that epithelial morphogeny (EPM) is engaged in differentiating hepatic stem/progenitor cells via the EPM-cytoskeleton CSK (-Mitosis spindle orientation MSO) system, which mediates biochemical-mechanical signals, using co-immunoprecipitation and micropatterning.